Action OCX ONCOCYTE CORPORATION
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues OncoCyte Corporation

Actions

OCX

US68235C2061

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 01/05/2024 		Varia. 5j. Varia. 1 janv.
2,55 USD +2,41% Graphique intraday de OncoCyte Corporation +3,66% +2,00%
16/04 Broadwood Capital, Inc. s'engage avec OncoCyte Corporation CI
12/04 Le secteur des soins de santé est stable avant la cloche vendredi MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
OncoCyte Corporation announced that it has received $15.807655 million in funding
Broadwood Capital, Inc. Engages with OncoCyte Corporation
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Oncocyte Reports Full Year 2023 Financial Results
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
OncoCyte Agrees to $15.8 Million Private Placement of Stock, Warrants
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Oncocyte : and Bio-Rad Partner on Global Launch of Transplant Assay - Form 8-K
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay
OncoCyte Corporation announced that it expects to receive $15.807655 million in funding
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays
Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays
OncoCyte: Q3 Earnings Snapshot
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Oncocyte Reports Third Quarter 2023 Financial Results
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action OCX
  4. Actualités OncoCyte Corporation
  5. Autres langues